Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
- PMID: 37267579
- PMCID: PMC10325768
- DOI: 10.1200/JCO.23.00723
Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Abstract
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.For generations, oncologists and urologists have used androgen deprivation therapy (ADT) to manage metastatic hormone-sensitive prostate cancer (mHSPC). Until recently, ADT monotherapy was standard. Within the past decade, a series of trials have clearly demonstrated improved outcomes with a more aggressive up-front approach. Doublet intensification therapy, involving either ADT plus docetaxel or ADT plus any of several second-generation oral androgen-receptor pathway inhibitors (ARPIs), provide considerable survival advantages compared with ADT alone. In 2022, two trials, PEACE-1 and ARASENS, demonstrated the potential of triplet therapy, adding an ARPI to an ADT-docetaxel doublet. In the Original Report that accompanies this article, the authors provide a post hoc analysis of ARASENS (ADT plus docetaxel, with or without darolutamide), identifying the subpopulations of patients with mHSPC who might benefit most from a triplet regimen. They segment the ARASENS cohort by disease volume and disease risk profile, finding that triplet therapy is associated with improved outcomes regardless of category (although with limited power in the low-volume cohort). Meanwhile, trials are ongoing examining the role of radiotherapy (RT) in mHSPC, a modality previously reserved for localized disease or isolated, symptomatic metastases. Here, we present a mHSPC case and discuss our approach to mHSPC considering recent studies. We recommend triplet therapy for patients who are suitable candidates for chemotherapy, especially for patients with high-volume disease. We also favor aggressive use of RT, when feasible, for patients with low-volume mHSPC.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
No other potential conflicts of interest were reported.
Figures
Similar articles
-
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.Eur Urol Focus. 2023 Sep;9(5):838-842. doi: 10.1016/j.euf.2023.03.024. Epub 2023 Apr 11. Eur Urol Focus. 2023. PMID: 37055323
-
[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].Urologie. 2023 Apr;62(4):360-368. doi: 10.1007/s00120-023-02029-0. Epub 2023 Feb 10. Urologie. 2023. PMID: 36763112 Free PMC article. Review. German.
-
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.Curr Oncol. 2022 Dec 4;29(12):9511-9524. doi: 10.3390/curroncol29120747. Curr Oncol. 2022. PMID: 36547161 Free PMC article.
-
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.Eur Urol Focus. 2023 Jan;9(1):96-105. doi: 10.1016/j.euf.2022.08.007. Epub 2022 Sep 1. Eur Urol Focus. 2023. PMID: 36058809 Review.
-
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19. Eur Urol. 2022. PMID: 35995644 Review.
Cited by
-
A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance.Front Immunol. 2024 Apr 17;15:1395047. doi: 10.3389/fimmu.2024.1395047. eCollection 2024. Front Immunol. 2024. PMID: 38694500 Free PMC article. Review.
-
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.Curr Treat Options Oncol. 2024 Mar;25(3):293-312. doi: 10.1007/s11864-023-01173-1. Epub 2024 Jan 4. Curr Treat Options Oncol. 2024. PMID: 38291265 Review.
-
Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer.Res Sq [Preprint]. 2023 Oct 24:rs.3.rs-3295914. doi: 10.21203/rs.3.rs-3295914/v1. Res Sq. 2023. PMID: 38076926 Free PMC article. Preprint.
References
-
- Helgstrand JT, Røder MA, Klemann N, et al. : Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer—A population-based analysis of 2 national cohorts. Cancer 124:2931-2938, 2018 - PubMed
-
- Tannock IF, de Wit R, Berry WR, et al. : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 - PubMed
-
- Eigl BJC, Eggener SE, Baybik J, et al. : Timing is everything: Preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 11:4905-4911, 2005 - PubMed
-
- Gravis G, Boher JM, Joly F, et al. : Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70:256-262, 2016 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous